Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Smart Nanomedicine for Cancer Diagnosis and Therapy
share announcement

Smart Nanomedicine for Cancer Diagnosis and Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 3910

Special Issue Editor

Prof. Dr. Tao Yang

E-Mail Website
Guest Editor
Jiangsu Key Laboratory of Neuropsychiatric Diseases, and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China
Interests: biomedical polymer; biomaterial; cancer theranostics; biomedical engineering

Special Issue Information

Dear Colleagues,

In recent years, nanomedicine has achieved remarkable breakthroughs in the field of cancer diagnosis and therapy with augmented outcomes. Furthermore, smart nanomedicine that sensitively responds to stimuli enables outstanding potencies with high selectivity and low toxicity. A variety of tumor-specific stimuli, such as glutathione (GSH), hydroperoxide (H2O2), acidity and hypoxia-activatable nanomedicine (both cargoes and drug carriers), have been explored to improve the accuracy of cancer diagnosis and efficacies of cancer therapy. Although great efforts have been devoted to developing tumor-activatable nanomedicine, it remains challenging to minimize off-target toxicities without interference in the therapeutic potency and diagnostic accuracy.

This Special issue aims to highlight recent advances in the field of smart nanomedicines for cancer diagnosis and therapy. In this Special Issue, research areas may include (but are not limited to) the following: activatable nanomedicines that are aimed at amplifying imaging signals for precise disease diagnosis, smart and multifunctional nanomedicines that confers monotherapy or combination therapy against malignant diseases (e.g., cancer), as well as the theranostic platform of imaging-guided therapy. Original research papers, and review articles are all welcome to be submitted to this special issue, “Smart nanomedicine for cancer diagnosis and therapy."

We look forward to receiving your contributions.

Prof. Dr. Tao Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stimuli responsiveness
  • smart nanomedicine
  • disease diagnosis
  • cancer therapy
  • imaging-guided therapy
  • nanotechnology
  • biomaterials

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 3687 KiB  
Article
Synergistic Phototherapy-Molecular Targeted Therapy Combined with Tumor Exosome Nanoparticles for Oral Squamous Cell Carcinoma Treatment
by Ming Li, Shiyao Yin, Anan Xu, Liyuan Kang, Ziqian Ma, Fan Liu, Tao Yang, Peng Sun and Yongan Tang
Pharmaceutics 2024, 16(1), 33; https://doi.org/10.3390/pharmaceutics16010033 - 26 Dec 2023
Viewed by 1130
Abstract
Oral squamous cell carcinoma (OSCC) contributes to more than 90% of all oral malignancies, yet the performance of traditional treatments is impeded by limited therapeutic effects and substantial side effects. In this work, we report a combinational treatment strategy based on tumor exosome-based [...] Read more.
Oral squamous cell carcinoma (OSCC) contributes to more than 90% of all oral malignancies, yet the performance of traditional treatments is impeded by limited therapeutic effects and substantial side effects. In this work, we report a combinational treatment strategy based on tumor exosome-based nanoparticles co-formulating a photosensitizer (Indocyanine green) and a tyrosine kinase inhibitor (Gefitinib) (IG@EXOs) for boosting antitumor efficiency against OSCC through synergistic phototherapy-molecular targeted therapy. The IG@EXOs generate distinct photothermal/photodynamic effects through enhanced photothermal conversion efficiency and ROS generation, respectively. In vivo, the IG@EXOs efficiently accumulate in the tumor and penetrate deeply to the center of the tumor due to passive and homologous targeting. The phototherapy effects of IG@EXOs not only directly induce potent cancer cell damage but also promote the release and cytoplasmic translocation of Gefitinib for achieving significant inhibition of cell proliferation and tumor angiogenesis, eventually resulting in efficient tumor ablation and lymphatic metastasis inhibition through the synergistic phototherapy-molecular targeted therapy. We envision that the encouraging performances of IG@EXOs against cancer pave a new avenue for their future application in clinical OSCC treatment. Full article
(This article belongs to the Special Issue Smart Nanomedicine for Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

21 pages, 4701 KiB  
Article
Comparison of Sonodynamic Treatment Set-Ups for Cancer Cells with Organic Sonosensitizers and Nanosonosensitizers
by Aleksandar Radivoievych, Svitlana Prylutska, Oliver Zolk, Uwe Ritter, Marcus Frohme and Anna Grebinyk
Pharmaceutics 2023, 15(11), 2616; https://doi.org/10.3390/pharmaceutics15112616 - 11 Nov 2023
Viewed by 1045
Abstract
Cancer sonodynamic therapy (SDT) is the therapeutic strategy of a high-frequency ultrasound (US) combined with a special sonosensitizer that becomes cytotoxic upon US exposure. The growing number of newly discovered sonosensitizers and custom US in vitro treatment solutions push the SDT field into [...] Read more.
Cancer sonodynamic therapy (SDT) is the therapeutic strategy of a high-frequency ultrasound (US) combined with a special sonosensitizer that becomes cytotoxic upon US exposure. The growing number of newly discovered sonosensitizers and custom US in vitro treatment solutions push the SDT field into a need for systemic studies and reproducible in vitro experimental set-ups. In the current research, we aimed to compare two of the most used and suitable SDT in vitro set-ups—“sealed well” and “transducer in well”—in one systematic study. We assessed US pressure, intensity, and temperature distribution in wells under US irradiation. Treatment efficacy was evaluated for both set-ups towards cancer cell lines of different origins, treated with two promising sonosensitizer candidates—carbon nanoparticle C60 fullerene (C60) and herbal alkaloid berberine. C60 was found to exhibit higher sonotoxicity toward cancer cells than berberine. The higher efficacy of sonodynamic treatment with a “transducer in well” set-up than a “sealed well” set-up underlined its promising application for SDT in vitro studies. The “transducer in well” set-up is recommended for in vitro US treatment investigations based on its US-field homogeneity and pronounced cellular effects. Moreover, SDT with C60 and berberine could be exploited as a promising combinative approach for cancer treatment. Full article
(This article belongs to the Special Issue Smart Nanomedicine for Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 1867 KiB  
Review
Advances in Polymeric Micelles: Responsive and Targeting Approaches for Cancer Immunotherapy in the Tumor Microenvironment
by Lichun Cheng, Jiankun Yu, Tangna Hao, Wenshuo Wang, Minjie Wei and Guiru Li
Pharmaceutics 2023, 15(11), 2622; https://doi.org/10.3390/pharmaceutics15112622 - 13 Nov 2023
Cited by 2 | Viewed by 1174
Abstract
In recent years, to treat a diverse array of cancer forms, considerable advancements have been achieved in the field of cancer immunotherapies. However, these therapies encounter multiple challenges in clinical practice, such as high immune-mediated toxicity, insufficient accumulation in cancer tissues, and undesired [...] Read more.
In recent years, to treat a diverse array of cancer forms, considerable advancements have been achieved in the field of cancer immunotherapies. However, these therapies encounter multiple challenges in clinical practice, such as high immune-mediated toxicity, insufficient accumulation in cancer tissues, and undesired off-target reactions. To tackle these limitations and enhance bioavailability, polymer micelles present potential solutions by enabling precise drug delivery to the target site, thus amplifying the effectiveness of immunotherapy. This review article offers an extensive survey of recent progress in cancer immunotherapy strategies utilizing micelles. These strategies include responsive and remodeling approaches to the tumor microenvironment (TME), modulation of immunosuppressive cells within the TME, enhancement of immune checkpoint inhibitors, utilization of cancer vaccine platforms, modulation of antigen presentation, manipulation of engineered T cells, and targeting other components of the TME. Subsequently, we delve into the present state and constraints linked to the clinical utilization of polymeric micelles. Collectively, polymer micelles demonstrate excellent prospects in tumor immunotherapy by effectively addressing the challenges associated with conventional cancer immunotherapies. Full article
(This article belongs to the Special Issue Smart Nanomedicine for Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop